Active Ingredient History

  • Now
Decernotinib is an inhibitor of Janus kinase 3 (JAK3) discovered through a process of inhouse screening of a chemical compound library. Decernotinib also had the name VX-509 in development phase. It is an experimental drug with high selectivity for JAK3, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). It is being studied in clinical trials at Vertex.   Wikipedia

  • SMILES: CC[C@@](C)(Nc1ccnc(n1)c2c[nH]c3ncccc23)C(=O)NCC(F)(F)F
  • Mol. Mass: 392.39
  • ALogP: 3.28
  • ChEMBL Molecule:
More Chemistry
2-((2-(1h-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-n-(2,2,2-trifluoroethyl)butanamide | adelatinib | decernotinib | vrt-831509 | vx-509


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue